Mandate

VINGE ADVISES PANDOX IN RELATION TO ITS LISTING ON NASDAQ STOCKHOLM

June 18, 2015

Vinge advises Pandox Aktiebolag (publ) in relation to its listing on Nasdaq Stockholm. A prospectus was published on 8 June 2015 and the first day of trading on Nasdaq Stockholm was 18 June 2015. The price in the offering was set at SEK 106 per share, corresponding to a market value of all shares issued by Pandox of SEK 15,900 million. The total value of the offering amounts to SEK 6,360 million, assuming that the over-allotment option is exercised in full.

Pandox is a leading owner of hotel properties located in Northern Europe with focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio comprises 104 hotels in the upper medium- and upscale segment with a total of 21,969 hotel rooms across eight countries. The market value of Pandox’s property portfolio amounted to SEK 27 billion as of 31 March 2015.

Vinge’s team consisted mainly of Jesper Schönbeck, Charlotte Levin, Erik Sjöman, David Andersson, Joakim Hagberg, Adam Sandberg and Ludvig Berke. Marie Brommesson assisted in due diligence, including financing and property related matters, and Maria Schultzberg and Tora Hansjons assisted in tax related matters.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026